<DOC>
	<DOC>NCT01617590</DOC>
	<brief_summary>This study was intended to assess the efficacy and safety of different Disease-Modifying Antirheumatic Drugs cycle combination regimen using the American College of Rheumatology (ACR) criteria of 20% improvement in symptoms (ACR20) in managing active adult rheumatoid arthritis.</brief_summary>
	<brief_title>Disease-Modifying Antirheumatic Drugs Cycle Combination Therapy Research</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Leflunomide</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>RA patientsï¼š Male and female patients aged 18 75 years (inclusive). Body weight between 50 and 100 kg (inclusive). Post menopausal or surgically sterile female patients are allowed. Female patients of childbearing potential may participate if they are already on a stable dose of methotrexate. Additional birth control details to be provided at screening. Male patients must use an effective contraception method during the study and at least for 2 months following the completion/discontinuation of the study. Diagnosis of RA, classified by American Rheumatism Association 1987 revised criteria. Active disease evaluation (DAS 28 &gt; 3.2). Patients who using steroids before enrollment, the dose should not be more than 30mg/d, and remain unchanged for more than 30days. Without use of other disease activity controlling drugs. Get the informed consent. Advanced patients with severe joints disability. Pregnant or breast feeding female patients. Patients with severe primary disease or impairment of heart, brain, lung, liver (ALT or AST &gt; 1.5 normal value), kidney (sCr &gt; normal value), endocrine, and hematology system. Concomitant with other rheumatic disease. Alcohol taken or drug abusing patients. Patients with congestive heart failure, QT prolongation syndrome or poorly controlled diabetes mellitus. Patients with a history of QTc prolongation will be excluded. Patients who have received intraarticular or systemic corticosteroid injections having been required for treatment of acute RA flare (not being part of a regular therapeutic regimen) within 4 weeks prior to randomization.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>RA</keyword>
	<keyword>Leflunomide</keyword>
	<keyword>Methotrexate</keyword>
</DOC>